LONDON, July 22 (Reuters) - AstraZeneca's muchanticipated cancer drug pipeline suffered a blow on Wednesdaywhen the experimental drug selumetinib failed to meet its goalin a late-stage trial for uveal melanoma.
The drugmaker said the setback would not affect otherstudies using the drug. Selumetinib is being investigatedprimarily as a treatment for advanced non-small cell lungcancer. (Reporting by Ben Hirschler, editing; by Louise Heavens)